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The newly emerging Middle East Respiratory Syndrome coronavirus
(MERS-CoV) causes a Severe Acute Respiratory Syndrome-like disease
with ∼43% mortality. Given the recent detection of virus in drome-
dary camels, zoonotic transfer of MERS-CoV to humans is suspected.
In addition, little is known about the role of human neutralizing Ab
(nAb) pressure as a driving force in MERS-CoV adaptive evolution.
Here, we used a well-characterized nonimmune human Ab-phage
library and a panning strategy with proteoliposomes and cells to
identify seven human nAbs against the receptor-binding domain
(RBD) of the MERS-CoV Spike protein. These nAbs bind to three dif-
ferent epitopes in the RBD and human dipeptidyl peptidase 4 (hDPP4)
interface with subnanomolar/nanomolar binding affinities and block
the binding of MERS-CoV Spike protein with its hDPP4 receptor. Es-
cape mutant assays identified five amino acid residues that are critical
for neutralization escape. Despite the close proximity of the three
epitopes on the RBD interface, escape from one epitope did not have
a major impact on neutralization with Abs directed to a different
epitope. Importantly, the majority of escape mutations had negative
impacts on hDPP4 receptor binding and viral fitness. To our knowl-
edge, these results provide the first report on human nAbs against
MERS-CoV that may contribute toMERS-CoV clearance and evolution.
Moreover, in the absence of a licensed vaccine or antiviral for MERS,
this panel of nAbs offers the possibility of developing human mAb-
based immunotherapy, especially for health-care workers.
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Middle East Respiratory Syndrome coronavirus (MERS-CoV),a newly emergent subgroup C betacoronavirus, was first iso-
dromedary camels had a high prevalence of neutralizing Abs (nAbs)
against MERS-CoV (11, 12). Recently, MERS-CoV has been
identified from dromedary camels on a farm associated with two
human cases, but the transmission patterns remain unclear (13).
More recently, a study detected Abs in all 151 samples of dromedary
camel serum obtained from the United Arab Emirates in 2003, in-
dicating that MERS-CoV or closely related CoVs existed in the
United Arab Emirates long before the first human MERS cases (14,
15). A screen of cell lines derived from livestock and peridomestic
small mammals on the Arabian Peninsula revealed that only
ungulates such as goats and camels showed efficient replication of
MERS-CoV (16). These findings suggest that bats and camels may
play an important role in MERS-CoV transmission and that the
range of species that can be infected with MERS-CoV may be
even broader than currently known (17).
The coronavirus S protein is a class I membrane fusion protein
that represents the major envelope protein on the surface of CoVs.
The S protein presents as a trimer and mediates receptor binding,
membrane fusion, and virus entry. S also is the major target for
nAbs (18). It has been reported that patients infected with MERS-
CoV generated S protein-specific nAbs (19, 20). The cellular re-
ceptor for MERS-CoV has been identified as dipeptidyl peptidase
4 (DPP4, CD26), which is conserved across many species (21). The
receptor-binding domain (RBD) of the virus S protein in complex
with human DPP4 (hDPP4) has been characterized (22, 23).
Although MERS-CoV has a lower reproduction number (R0)
than SARS-CoV (0.69 vs. 0.80) (2), it has a much higher mor-
tality rate (43% vs. 10%). Currently, no licensed vaccines or
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lated in the Arabian Peninsula in 2012 (1). Similar to the Severe 
Acute Respiratory Syndrome coronavirus (SARS-CoV) that 
emerged in China in 2002, MERS-CoV causes severe respiratory 
tract infection, often in the lower respiratory tract and occasionally 
accompanied by renal disease (1). As of February 28, 2014, 184 cases 
with 80 deaths have been confirmed in 10 countries in the Middle 
East, Europe, and North Africa (www.who.int/csr/don/2014_02_28/
en/). Although the human-to-human transmission rate is mild to 
moderate at the moment (2, 3), the increasing number of person-to-
person transmissions raises concern for a more widespread regional 
outbreak or even global spread by international travelers, as oc-
curred with SARS-CoV in 2002–2003. Limited information exists on 
the mechanisms that confer increased human-to-human trans-
mission of MERS-CoV (4). However, mutational adaptation of the 
SARS-CoV Spike (S) protein for its receptor, angiotensin-converting 
enzyme 2 (ACE2) was a positive selection factor after zoonotic 
transfer to humans (5, 6).
Phylogenetic analysis indicates that MERS-CoV is closely related 
to CoVs detected in Tylonycteris pachypus and Pipistrellus abramus 
bats in China, Nyctinomops laticaudatus bats in Mexico, and Nycteris 
cf. gambiensis bats in Ghana and Europe (7–9). An ∼190-bp nucle-
otide fragment that was genetically identical to the RNA-dependent 
RNA polymerase of MERS-CoV was detected in Taphozous perfo-
ratus bat specimens in the vicinity of the index case in Saudi Arabia 
(10). Two independent serological surveys of livestock found that
antivirals are available for the prevention or treatment of MERS.
Combination treatment with IFN-α2b and ribavirin can moderate
the host response and has been reported to improve clinical out-
comes in MERS-CoV–infected rhesus macaques (24). MERS-CoV
S protein vaccines based on modified vaccinia virus Ankara or
Venezuelan Equine Encephalitis replicon particles and purified
RBD can induce virus nAbs in mouse models (25–27). How-
ever, results of human studies have not been reported. Thus, an
urgent medical need remains for the targeted prophylaxis and
treatment of MERS.
Human Ab engineering is a powerful tool that has been used
for both discovery and therapeutic applications. We and others
have proposed previously that human mAbs could be used in
a outbreak setting for the prophylaxis and early treatment of
emerging viral pathogens (28, 29). However, obtaining timely
access to biological specimens from infected patients as a source
of B cells for targeted selection or Ab-phage library construction
is often challenging and can delay the discovery process (30–33).
These restrictions have led us to use an ultra-large nonimmune
human Ab-phage display library as a resource for the isolation of
human nAbs to several emerging pathogens (29, 34, 35). With
this Ab library resource and a unique panning strategy, we report
the isolation and characterization of seven human nAbs that bind
to three different epitopes at the MERS-CoV RBD–hDPP4 in-
terface. We also investigated nAb-driven virus evolution and
identified residues on the RBD that are critical for neutralization
escape. These studies provide insight into the human nAb re-
sponse that appears to impact MERS-CoV fitness and evolution.
In addition, this panel of nAbs offers the possibility of de-
veloping a human mAb-based immunotherapy for the prevention
and treatment of MERS.
Results
Identification of Anti-MERS Spike Phage Abs by Sequential Spike-
Containing Paramagnetic Proteoliposome and Spike-Expressing 293T
Cell Panning. Purified Spike-containing paramagnetic proteoli-
posomes (S-PMPLs) and Spike-expressing 293 T cells (S-293T)
were used to select Abs from the Mehta I/II nonimmune human
single-chain variable domain fragment (scFv)-phage libraries.
After two rounds of selection with S-PMPLs and one subsequent
round of selection with S-293T cells, a total of 1,344 clones were
screened to verify their binding to S1 and S2 fused with constant
region fragment of human IgG (hFc) (Fig. S1) by ELISA or meso-
scale discovery (MSD). Seventy-nine clones were positive against
S1-hFc, accounting for all the positive clones binding to S-293T
cells, as confirmed by flow cytometric analysis. Further sequencing
indicated that the 79 positive clones represented seven unique
anti-S1 scFvs (1E9, 1F8, 3A1, 3B12, 3C12, 3B11, and M14D3).
Fig. 1 shows the amino acid sequences of these clones. Three
different germ-line sequences from the variable region of the
heavy chain (VH) and six different germ-line sequences from the
variable region of the light chain (VL) are represented. Five of
seven VH chains belong to one gene family, IGHV1-69 (four 06
alleles and one 09 allele). Remarkably, these VH segments show
very low levels of somatic hypermutation (SHM) (mean 4.3 ±
4.2), ranging from zero (3B12, 3B11) to only five (3A1, 3C12)
amino acid substitutions. 1E9 and 1F8 Abs use VH3-30 and VH1-3
and have 10 and 9 substitutions, respectively. The lengths of the
VH complementarity-determining region 3 (CDR3) for these
seven Abs vary from 11 to 19 amino acids. The VL genes are
more diverse. Four VLs use κ chains, and three use λ chains.
However, they also show a low level of SHM (mean 5.3 ± 2.4).
S1 Domain Epitope Mapping and Binding Competition. To delineate
the S1 epitopes of these Abs more precisely, the S1 domain was
expressed as three fragments: S1(21–358), S1(349–751), and
S1(349–590) (Fig. S1). Each fragment was designed with an
N-terminal Flag tag and a C-terminal hFc tag. Binding detection
with Octet showed that all seven scFvFcs recognized S1(349–
751)-hFc and S1(349–590)-hFc but not S1(21–358)-hFc (Fig.
S2). These results demonstrate that the epitopes of all seven Abs
lie within the 349–590 amino acid fragment of the S protein,
which contains the RBD of MERS-CoV (36).
To determine whether these Abs recognize different epitopes,
binding competition assays were performed. An anti-Flag bio-
sensor capturing S1(349–590)-hFc initially was saturated with
one Ab, and additional binding with another Ab was evaluated.
The results indicate that 1E9 can block the binding of 1F8 and
3A1 completely and can block 3B12 and M14D3 partially but
does not affect the additional binding of 3B11 and 3C12 (Fig.
S3A). Abs 1F8, 3A1, and 3B12 can block the binding of all other
Abs to S1(349–590) (Fig. S3 B–D). Additionally, 3B11, 3C12,
and M14D3 can block the binding of 1F8, 3A1, and 3B12, but
not 1E9, to S1(349–590) (Fig. S3 E–G). The results indicate that
the seven Abs recognize at least three distinct epitope groups,
although Ab-RBD cocrystallization will be necessary to de-
termine the precise atomic details of the epitopes and the Ab
binding orientations. Ab 1E9 recognizes one unique epitope
(group 1); 1F8, 3A1, and 3B12 recognize another epitope or
overlapping epitopes close to each other (group 2); and 3B11,
3C12, and M14D3 recognize a third distinct epitope or group of
epitopes (group 3). In addition, the ability of epitope 2 Abs to
block RBD binding of all Abs suggests that epitope 2 most likely
is located centrally, whereas epitopes 1 and 3 are flanking, a
Fig. 1. Amino acid sequences of variable regions of anti–MERS-CoV Spike mAbs. Framework regions 1–4 (FR1–4) and CDR1–3 for VH and VL are shown. FR, CDR, and
germ line are defined according to the International Immunogene Tics database. Hyphens denote gaps. SHMs are highlighted in red. Because PCR priming may bias
the first six amino acids of rearranged VH and VL segments, these amino acids were not included in SHM analysis and are colored in blue. Germ, germ-line gene.
conclusion that also is supported by neutralization escape data
with MERS-CoV (described below).
Ab Binding Affinity and Neutralization Activity of Anti-Spike scFvFcs
and IgGs. Binding rate constants [equilibrium dissociation con-
stant (Kd), Kon, and Koff] of each scFvFc and their fully converted
IgG1 forms to S1(349–590) were measured by bio-layer in-
terferometry (BLI) using an Octet RED96 (Fig. S4). All Abs
had nanomolar to subnanomolar binding affinity to S1(349–
590) (Table 1). Although it is uncharacteristic in our hands to
see a significant loss of binding affinity on scFvFc-to-IgG1 for-
mat changes, conversion of three of the seven scFvFcs (3A1,
3B12, and M14D3) to IgG1 resulted in ∼11- to 34-fold higher Kd
values, which mostly were attributable to faster Koff rates. For the
other four Abs, the IgG1 forms had lower Kd values than their
scFvFc counterparts and therefore had higher binding affinities.
We then tested the neutralization activities of these Abs on
hDPP4-expressing 293T cells (293T-hDPP4) with MERS-CoV S
pseudotyped lentiviruses (VLPs) carrying a luciferase reporter
gene. Although all anti–MERS-S1 Abs can neutralize MERS
pseudovirus infection specifically with varying efficiency, 3B11
exhibited the best pseudovirus neutralization activity in both the
scFvFc and IgG1 formats (Fig. 2 A and B). To investigate the
possible effect of S density on the neutralization potential of
the Abs, we compared pseudovirus neutralization with the neu-
tralization of live MERS-CoV infection of Vero cells using plaque
reduction neutralization tests (PRNT50). The results indicated
that all scFvFcs strongly neutralized MERS-CoV with varying
degrees of efficiency. Abs 3B11, 3A1, 3B12, and 3C12 were very
strong neutralizers, with 50% inhibitory concentration (IC50)
values ranging from 1.25 to 2 μg/mL. The other three scFvFcs,
1E9, M14D3, and 1F8, neutralized the virus with IC50 values of
3.21, 4.3, and 6.27 μg/mL, respectively (Table S1). At concen-
trations ≥20 μg/mL, six of seven scFvFcs neutralized MERS-CoV
completely (Fig. 2C). Three IgG1 Abs also were tested for live
virus neutralization; 3B11 had a lower IC50 value than 1F8 and
3A1 IgGs (Table S1). The anti-SARS S mAb 80R did not neu-
tralize MERS-CoV (Fig. 2D) (35).
For pseudovirus neutralization, 1F8, 1E9, 3B11, and 3C12
IgG1 had neutralization activities similar to those of their scFvFcs,
in agreement with their similar binding affinities, whereas 3A1,
3B12, and M14D3 IgGs had lower neutralization activities than
their scFvFcs, in agreement with their lower binding affinities
(Fig. 2B and Table 1). Thus, as expected, virus neutralization
potency was positively correlated with nAb binding affinity, with
3B11 being the most potent nAb in both formats.
Mechanism(s) of MERS-CoV Neutralization. We next explored the
mechanism(s) of neutralization by investigating whether these
Abs could block hDPP4 binding to the RBD and vice versa.
Binding competition between hDPP4 and scFvFcs was con-
ducted with Octet with a technique similar to that used to detect
the competition between each Ab (Fig. S3). As shown in Fig. 3A,
all scFvFcs could block hDPP4 binding to S1(349–590), whereas
preloading of control scFvFc (F10) did not affect hDPP4 binding
to S1(349–590). Similarly, hDPP4 also could block all seven
scFvFcs from binding to S1(349–590) (Fig. 3B).
To investigate whether these Abs can block virus attachment
to cells, we next examined whether scFvFcs can inhibit S protein
(Fig. S5A) or S-VLP (Fig. S5B) binding to hDPP4-expressing
cells. As shown in Fig. S5A, all scFvFcs (except for 3B11, which
gave maximal inhibition at all tested concentrations) could in-
hibit 50 nM S1(349–590)-hFc binding to 293T-hDPP4 cells in
a dose-dependent manner. The control scFvFc, F10, did not
inhibit S1(349–590)-hFc binding to 293T-hDPP4. In addition,
Fig. S5B shows that all scFvFcs could inhibit the attachment of
MERS S pseudovirus to hDPP4-expressing cells.
Generation of Ab Escape Mutants. To investigate virus evolution
under nAb pressure, we performed escape studies for all seven
scFvFcs and three full-length IgG1s. Upon three rounds of se-
lective pressure in the presence of each Ab, escape mutants for
all the scFvFcs and for two of three IgG Abs were generated; no
escape mutant was isolated for 3B11 IgG.
To map the mutations in the S protein that conferred escape
to each Ab, all escape mutants were plaque purified, and the S
protein-coding regions were sequenced. Only one or two amino
acid substitutions conferred escape to each Ab (Fig. 4A). In-
terestingly, all the escape mutations mapped to the patch 2 re-
gion in the receptor-binding motif (RBM; amino acids 484–567)
that interfaces with the hDPP4 (Fig. 4B), except for the escape
mutant of 1F8 IgG1, which also had a distant substitution (I1229
T) in the S2 domain. Importantly, these escape mutations mir-
rored the Ab competition studies (Fig. S3) and confirmed the
presence of three epitopes. Ab 1F8, 3A1, and 3B12 bind to
amino acids in the center of the RBM, whereas 1E9 binds to
epitope 1, and 3B11, 3C12, and M14D3 bind to another flanking
epitope, epitope 3.
Escape Mutations Affect Abs’ Binding and Cross-Neutralization. To
investigate the affinities of the anti-S1 Abs binding to RBD
mutants, seven RBD mutants were constructed, purified, and
subjected to Octet analysis. As shown in Table S2, all seven Abs
could bind to the L506F mutant with 0.52- to 7.7-fold affinity
changes compared with their binding to the wild-type RBD.
There also was a modest change of ∼0.97- to 5.26-fold binding
affinity of all Abs to the P547S mutant. In addition, with the
exception of 1E9 (epitope 1 Ab), binding affinity for all Abs to
the other five RBD mutants carrying T512A, Y540C, or R542G
mutations fell below the level of Octet detection. Interestingly,
1E9 maintains good binding affinity with both the Y540C mutant
and the L506F and Y540C mutants, supporting the idea that1E9
binds to a distinct epitope, epitope 1, that does not overlap with
epitope 3.
Table 1. Kinetic rates and binding affinity of anti–MERS-CoV Abs
Ab
scFvFc IgG IgG/scFvFc*
Kd, M Kon, 1/Ms Koff, 1/s Kd, M Kon, 1/Ms Koff, 1/s Kd Kon Koff
1E9 4.13E-10 7.91E+05 3.26E-04 2.61E-10 8.75E+05 2.28E-04 0.63 1.11 0.70
1F8 1.58E-09 6.68E+05 1.05E-03 1.11E-09 6.52E+05 7.22E-04 0.70 0.98 0.69
3B12 1.76E-10 1.16E+06 2.04E-04 2.24E-09 2.09E+06 4.68E-03 12.73 1.80 22.94
3A1 2.25E-10 5.04E+05 1.13E-04 2.43E-09 1.68E+06 4.08E-03 10.80 3.33 36.11
3C12 2.01E-09 4.85E+05 9.76E-04 4.44E-10 2.82E+06 1.25E-03 0.22 5.81 1.28
3B11 1.35E-10 1.21E+06 1.64E-04 5.70E-11 1.24E+06 7.06E-05 0.42 1.02 0.43
M14D3 4.74E-11 1.58E+05 7.51E-06 1.59E-09 1.61E+05 2.56E-04 33.54 1.02 34.09
The kinetic constants were obtained by global analysis using a 1:1 binding model using Fortebio Data Analysis 7.0 software. 
*Ratio of each rate.
Effects of Escape Mutations on Viral Fitness. To investigate how the
escape mutations affect RBD–hDPP4 interaction and viral fitness,
the binding affinities of seven mutated RBDs to hDPP4 were
analyzed. As shown in Table S2, L506F and P547S had minimal
effects on RBD–hDPP4 affinity, whereas the other three muta-
tions (T512A, Y540C, and R542G) resulted in undetectable
binding between the RBD mutants and hDPP4. To investigate
these findings further, the RBD mutants were analyzed for hDPP4
binding by FACS, a more sensitive measure that may detect low-
affinity binding. As shown in Fig. 5A, all seven mutated RBDs can
bind to 293T-hDPP4 cells with varying efficacy. The P547S mu-
tation did not change RBD binding to hDPP4 cells. However, the
L506F single substitution caused an approximately threefold
higher 50% effective concentration (EC50) than the wild-type
RBD, whereas the other five mutants resulted in 10- to 25-fold
higher EC50 values compared with the wild-type RBD.
Six escape mutant viruses were chosen for further investi-
gation of viral fitness (note that the Em1F8-IgG, Em3A1-IgG,
and EmM14D3-Fc escape viruses were not evaluated because
their substitutions are at R542, the same residue as in the chosen
Em1F8-Fc and Em3A1-Fc escape viruses). All six neutralization
escape viruses grew in Vero cells, reaching peak titers of 106–108
pfu/mL by 36 h after infection (Fig. 5B). Escape mutants Em3B11-
Fc and Em3A1-Fc had 1- to 2-log reductions in titer at 12–36 h after
infection, compared with the wild-type virus. Em1F8-Fc, Em3B12-
Fc, and Em3C12-Fc had two- to fivefold reductions in titer, and
Em1E9-Fc had a slightly increased viral titer. These results suggest
that, by kinetic and peak titer assessment, most of the escape
mutations resulted in impaired fitness.
We next compared the contact changes between the RBD and
hDPP4 before and after neutralization escape to determine the
potential atomic causes of changes in binding affinity. L506,
W553, and V555 in the RBD and L294 and I295 in hDPP4 form
a hydrophobic core in patch 2 at the protein–protein interface
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Fig. 2. Neutralization with MERS-VLPs (A and B) or live virus (C and D). Serially diluted scFvFc (A) and IgG1 (B) were tested with MERS-VLPs. For the
pseudovirus neutralization assay, anti-influenza HA mAb (F10) was used as a negative Ab control, and VSV-G pseudotyped virus was used as pseudovirus
control for neutralization specificity. Seven scFvFcs (C) and three IgG1s (D) were tested by PRNT50 assay with live MERS-CoV. The anti-SARS S mAb 80R was
used as a negative Ab control.
Additional PRNT50 assays were performed to assess whether 
higher concentrations of the selecting Ab could neutralize its 
escape virus (Fig. S6). All the escape mutants selected by these 
nAbs clearly escaped from their parent Abs, and eight of the 
escape mutants had IC50 values of ≥20 μg/mL Only Em3B11-Fc 
achieved an IC50 value of 6.76 μg/mL, a 3.7-fold increase com-
pared with wild-type virus (Table S1).
Based on the epitope-mapping studies and locations of the 
escape amino acid changes, mutant viruses were assigned to 
three epitope groups. Cross-neutralization (PRNT50) assays were 
performed to analyze whether Abs of one group could still 
neutralize escape mutant viruses generated by Abs of another 
epitope group. IC50 values (Table S3) indicated that 1E9-Fc 
(group 1 Ab) could still neutralize escape viruses generated from 
group 2 (Em1F8-Fc) and group 3 (Em3B11-Fc, Em3C12-Fc) 
Abs; 1F8-Fc (group 2 Ab) could neutralize escape viruses gen-
erated from the group 1 (Em1E9-Fc) Ab and the group 3 
[Em3B11-Fc (Y540C and L506F)] Ab with IC50 = 11.2 μg/mL, 
but not another group 3 [Em3C12-Fc (Y540H)]Ab with IC50 >40 
μg/mL. Additionally, 3B11-Fc and 3C12-Fc (group 3 Abs) still 
could neutralize escape viruses from group 1 (Em1E9-Fc) and 
group 2 (Em1F8-Fc) Abs, although 3C12-Fc neutralizes Em1F8-
Fc with an approximately sixfold higher IC50 (11.7 μg/mL). As 
expected, 1F8-Fc (a group 2 Ab) did not neutralize Em3A1-Fc (a
group 2 escape virus) (IC50 >40 μg/mL). The 3B11-Fc (a group 3 
Ab) could neutralize Em3C12-Fc (a group 3 escape virus) at a 
higher Ab concentration (IC50 = 8.94 vs. 1.83 for wild type), and 
3C12-Fc (a group 3 Ab) could neutralize Em3B11-Fc (a group 3 
escape virus) at a much higher Ab concentration (IC50 = 13.8 vs. 
2.0 for wild type) (Table S3). These results indicate that a ma-
jority of these escape viruses generated from one Ab epitope 
group confer resistance to neutralization within the same Ab 
epitope group but not to a different Ab epitope group.
(23). As shown in Fig. S7 A and B and Table S4, the L506F
substitution is predicted to result in a net decrease of four van
der Walls (VDW) contacts between the RBD and hDPP4;
however, the conserved hydrophobic L506F mutation may not
change this hydrophobic core appreciably, in contrast to the
significant loss of hDPP4 binding and cell-entry capacity with an
L506A pseudovirus (23). The P547S substitution likely does not
change the interaction of the RBD and hDPP4, because it is not
in direct contact with hDPP4. In addition, although the orien-
tation of the T512 side chain is not directly in contact with
hDPP4, it makes 20 internal contacts within a loop structure that
connects β-strands 6 and 7 (22). The T512 side chain does form
an important hydrogen bond with D509 that may stabilize the
loop structure (Fig. S7C). This hydrogen bond is lost with the
T512A substitution, along with a 25% loss of other internal loop
contacts (Fig. S7D). These atomic changes may alter the local
conformation of the RBD, resulting in a decrease in hDPP4
binding (Table S4). In addition, although Y540 and R542 on the
RBD can form hydrogen bonds with T265 and L294 on hDPP4,
respectively (Fig. S7A), the Y540C substitution results in
a shorter side chain, and the R542G substitution removes the
side chain of this residue. These two substitutions may change
the RBD–hDPP4 interaction dramatically, as illustrated in Fig.
S7 A and B and Table S4, where Y540C and R542G substitutions
resulted in a net of four and 11 decreases in VDW contacts
between the RBD and hDPP4, respectively.
Discussion
In this study, we isolated seven anti–MERS-CoV Spike nAbs
from a nonimmune human Ab-phage library using a novel pan-
ning strategy. These nAbs bind to three different epitopes in the
RBD–hDPP4 interface with subnanomolar to nanomolar affinity
and neutralize MERS-CoV infection. At least one major mecha-
nism of action is their capacity to inhibit S protein binding to its
DPP4 receptor. The residues within the RBD critical for neutrali-
zation were identified through the generation of escape variants and
were confirmed by kinetic binding studies. Despite the close prox-
imity of the three epitopes on the RBD interface, escape from
one epitope minimally altered other Ab neutralization directed
to a different epitope. Importantly, the majority of escape muta-
tions had negative impacts on hDPP4 receptor binding and viral
fitness. These results provide insight into the basis and biases of
human nAbs against MERS-CoV that may contribute to MERS-
CoV clearance and evolution.
We used mammalian cell-produced full-length S protein
expressed on PMPLs and cell surfaces for Ab panning. Surpris-
ingly, all Abs identified were directed to the RBD and have
potent neutralizing activity. With this same Ab-phage library,
A B
Fig. 3. Competition for binding to the MERS S RBD between anti-S1 Abs and hDPP4. Immobilized S1(349–590)-hFc (RBD-hFc) was saturated with 100 nM of
scFvFc (A) or hDPP4 (B), and the RBD sensors then were exposed to hDPP4 (A) or scFvFc (B). The binding properties were monitored on an Octet RED96. F10
was used as a nonbinding control.
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Fig. 4. Escape mutations. (A) Amino acid differences among the RBDs of the S proteins of natural isolates and escape mutants (Em). (B) Diagram of the
escape mutations in the RBD. The structure was adapted from Protein Dana Bank (PDB) ID code 4KR0. The RBM (amino acids 484–567) is colored in purple. The
receptor-binding core is colored in light blue. The hDPP4 is colored gray. Three proposed epitopes are depicted as solid circles: epitope 1 in cyan, epitope 2 in
magenta, and epitope 3 in green. Escape mutation residues are colored based on their corresponding epitope locations. Two major binding patches are
shown by dotted circles shaded light green (patch 1) and orange (patch 2).
the RBD and that a prolonged affinity maturation process is not
required to develop a potent nAb response. In addition, there
are 14 IGHV1-69 alleles and significant copy number variation
(CNV), from zero to five copies, because of gene deletion and
duplication (43, 44). The IGHV3-30 and IGHV1-3 germ-line
genes used by 1E9 and 1F8, respectively, also have multiple
alleles and have been reported for other anti-viral Abs (39, 45).
Whether this Ig polymorphism and CNV can influence the early
nAb response to and the clinical outcome of MERS-CoV in-
fection is not known. The limited clinical data that are available
have reported only that most MERS patients have had immu-
nosuppression and/or underlying disease (46, 47).
Human DPP4 binds to the MERS-CoV RBD with a Kd of
∼21.4 nM, which is comparable with a previous report 16.7 nM
(22). All seven nAbs bind to the RBD with 10- to 450-fold higher
affinity than to hDPP4. Previous studies have indicated that
higher Ab affinity confers broader and higher neutralizing ac-
tivity (48). Here, we dissect the contributions of binding affinity
and epitope specificity toward defining nAb activities. When
binding to the same epitope, nAbs with higher binding affinity
had higher neutralizing activity. Among the epitope group 2 Abs,
3A1 scFvFc had a higher affinity than 1F8 and exhibited better
neutralization activity (Fig. 2A and Table 1). Among the epitope
group 3 Abs, 3B11 scFvFc/IgG had a higher affinity and showed
better neutralizing activity than 3C12 scFvFc/IgG (Fig. 2 A and B
and Table 1). However, when nAbs bind to different epitopes,
the nAbs binding to the center of the RBD–hDPP4 interface are
more potent. For example, the epitope group 1 Ab 1E9 has
strong binding affinity to the RBD but has weak neutralization
activity (Fig. 2A and Table 1), perhaps because 1E9 binds to the
small η4 helix that is close to but distinct from the RBD–hDPP4
interface. Binding to this position may not completely block
hDPP4 binding to the RBD. In contrast, 3C12 has lower binding
affinity than 1E9 but has better neutralization activity because it
binds directly at the RBD–hDPP4 interface (Fig. 4B).
The generation of neutralization escape mutants can be a
helpful tool for identifying residues critical for neutralization
and for investigating virus evolution under immune pressure
(37, 49). Like other RNA viruses, CoVs have high mutation rates,
especially during cross-species transmission, that are important
for virus adaptation to new host receptors (5, 6, 50). Immune
pressure is another force selecting for virus mutation (37, 49).
With the exception of the 3B11 IgG, which appears to have
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Fig. 5. Characterization of RBD mutants. (A) Analysis of EC50 for the RBD mutant proteins binding to 293T-hDPP4 cells. Each purified RBD mutant, con-
structed with an hFc tag, was serially diluted 2× (12 dilutions starting from 5 or 20 μg/mL) and then was incubated with 1 × 105 293T-hDPP4. The binding of the
RBD mutant proteins was monitored with APC-Cy7–labeled anti-hFc Abs by FACS. (B) In vitro growth kinetics of nAb escape mutant MERS-CoVs. Vero cells
were infected with 0.1 MOI of escape mutant or wild-type MERS-CoV for 1 h in triplicate. Then unbound viruses were removed, growth medium was
replenished, culture supernatants were sampled in triplicate at indicated time points, and virus titers were determined by plaque assay on Vero cells.
we previously had identified potent neutralizing Abs against 
SARS-S and broadly cross-neutralizing Abs against the fusion 
peptide of West Nile virus E protein and the hemagglutinin stem 
domain of influenza A viruses (29, 34, 35, 37). In contrast to our 
previous report on the isolation of RBD-directed nAbs against 
SARS-CoV using immunotube-bound S1 protein as bait (35), the 
combined strategy of sequentially using full-length S protein 
expressed on PMPLs and then on cells as bait resulted in a 
higher recovery of potent nAbs and further demonstrates that 
the RBD interface is dominant in our selection system. The 
presentation of the native S glycoprotein as an intact trimer on 
PMPLs and cells may present the S1 domain more effectively 
than the S protein immobilized on immunotubes. Thus, this 
technology again has proven valuable for obtaining potent hu-
man nAbs in the absence of specimens from immune patients 
containing plasmablasts or memory B cells (31, 38). This dis-
tinction is particularly important when early access to patient 
specimens is problematic, in part because of government, regu-
latory, and biocontainment restrictions. Thus, this rapid response 
platform is well positioned to isolate and characterize robust 
immunotherapeutics against future emerging viruses quickly.
Abs typically accumulate 5–20% amino acid changes in their 
V-segments during the affinity maturation process, which consist 
of 6–25 amino acid changes in the VH or VL domains (39). 
NAbs against HIV gp120 often have amino acid changes of 
19–46% in their VH genes alone (40). The seven anti-Spike 
nAbs described here use three VH and six VL germ-line genes 
with 0–10 SHMs. Interestingly, five of seven Abs use the IGHV1-69 
germ-line gene that is preferentially used by many anti-viral 
nAbs, including those directed against hepatitis C virus and in-
fluenza viruses (34, 39, 41). IGHV1-69 is the only VH gene that 
has two hydrophobic residues at the tip of its CDR–H2 loop that 
can make direct contact with the viral glycoprotein (42). The Abs 
3B11 and 3B12 use the IGHV1-69*06 germ-line gene without 
any SHMs and have only nine or three SHMs in their light 
chains, respectively, but they maintain subnanomolar binding 
affinities for S. The hydrophobic core of patch 2 at the RBD–
hDPP4 interface is in the center of these epitopes. We suggest 
that the IGHV1-69 Abs may replace hDPP4 and make direct 
contact with this hydrophobic core through their CDR–H2 loops 
(23). Our finding that no to only a few SHMs are required for 
RBD binding further suggests that a potentially greater number 
of IGHV1-69 B-cell receptor precursors may be able to recognize
high affinity and lack of neutralization escape, the 3B11 IgG
should be included in this mAb mixture. In addition, our im-
munogenetic results provide the basis for comparisons with more
global antibodyome studies of circulating B cells from MERS-
CoV–infected patients during acute and/or convalescent phases
of infection and an opportunity to examine the role that Ig
polymorphism may play in shaping the protective Ab repertoire
and influencing clinical responses (44, 56).
Materials and Methods
Expression and Purification of the MERS-CoV Spike. The MERS-CoV S gene
(according to GenBank accession no. JX869059) was codon-optimized and
synthesized for mammalian cell expression. The full-length Spike with a Flag tag
(DYKDDDDK) at its N terminus (between the signal peptide and the extra-
cellular domain of the S protein) and a C9 tag (TETSQVAPA) at its C terminus
was first cloned into the pcDNA3.1 vector. Subsequently a series of con-
structs encoding different fragments of MERS-CoV Spike protein was
designed. Plasmids encoding MERS-CoV S protein residues 21–751, 752–
1295, 21–358, 349–751, and 349–590 fused with the CD5 signal peptide
and the constant region fragment of human IgG1 were named S1-hFc,
S2-hFc, S1(21–358)-hFc, S1(349–571)-hFc, and S1(349–590)-hFc (RBD-hFc),
respectively (Fig. S1). The last-named three constructs also have Flag tags
at their N termini. Fc-tagged proteins were expressed from transiently
transfected 293T cells and were purified with protein A Sepharose
(GE Healthcare).
Stable 293T Cells Expressing MERS-CoV Spike or Human DPP4. Full-length S with
an N-terminal Flag tag and a C-terminal C9 tag was cloned into the pHAGE
lentiviral vector, which can express both S and ZsGreen via an internal ribosome
entry site sequence. Corresponding lentiviral particles pseudotyped with Ve-
sicular stomatitis virus-G (VSV-G) envelope proteins were produced from Lenti-
X 293T cells as described andwere used for 293T cell transduction (57). The cells
expressing the MERS S protein then were sorted by flow cytometry with GFP.
After 2–3 wk of propagation, stable S-293T cells were sorted again with anti-
Flag Ab and set aside for future experiments. hDPP4 was RT-PCR–amplified
from human peripheral blood mononuclear cells and then was cloned into
a pHAGE vector without a ZsGreen reporter gene. Stable 293T-hDPP4 cells
were established following a protocol similar to the one described above.
Preparation of MERS Spike-PMPLs. The S-PMPLs were prepared as described
elsewhere (58, 59). Briefly, 1 × 108 S-293T cells were lysed with lysis buffer and
then were incubated with 5 × 108 M-280 Tosylactivated Dynabeads (Dynal
Biotech) coated with C9 tag mAb (1D4). The Spike-bound beads were washed
extensively and resuspended in 1.25 mL buffer containing 100 mM (NH4)2SO4,
20mM Tris (pH 7.5), 10% (vol/vol) glycerol, and 1mg/mL lipid mixture consisting of
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine/1-Palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine/1,2-Dioleoyl-sn-glycero-3-phosphate (POPC/POPE/DOPA)
(6:3:1; Avanti Polar Lipids). The protein-liposome mixture was dialyzed to re-
move the detergent slowly and to allow the formation of proteoliposomes. The
dialyzed beads were washed twice with 0.1% BSA/PBS and then were resus-
pended in 0.1%BSA/PBS to a concentration of 1 × 109/mL. The protein com-
position of S-PMPL and of control 293T-PMPL cells then was analyzed by
SDS/PAGE and Western blot.
Selection of Phage Abs by Panning with S-PMPLs and S-293T Cells. Two com-
bined human scFv libraries (Mehta I/II) (∼27 billion members) constructed
from B cells of 57 unimmunized donors were mixed and used for selection of
scFvs against MERS-CoV S. 293T cells, 293T-PMPLs, and S-PMPLs were pre-
blocked in 2% BSA/2% nonfat milk/PBS for 1 h at room temperature. An
aliquot of the mixed phage library (5 × 1012 pfu) was incubated with 3 × 107
293T cells and 3 × 107 293T-PMPLs three times to remove the nonspecific
phage clones. Preabsorbed phage was incubated with 2 × 107 S-PMPLs in
2 mL of 2% BSA/2% nonfat milk/PBS for 2 h at room temperature with
gentle shaking. Nonspecifically absorbed phages were removed by intensive
washing with PBS containing 0.1% Tween 20. Specifically bound phages
were eluted with 100 mM triethylamine and then were neutralized, ampli-
fied, and used for the next round of panning. After two rounds of panning
with S-PMPL, the eluted phages were incubated directly with S-293T cells,
followed by PerCP-Cy5.5–labeled anti-M13 Ab staining. PerCP-Cy5.5 and GFP
double-positive cells were sorted by FACS and used to infect TG1 cells.
Randomly picked single phage-scFv clones were screened for specific binding
to S1-hFc and S2-hFc by MSD and ELISA as previously described (35, 59). The
VH and VL of MSD/ELISA-positive clones were sequenced and aligned for the
identification of unique Ab clones.
a binding affinity below the neutralization escape threshold 
(Table 1), all other Abs, including 3B11 scFvFc, underwent 
neutralization escape. Based on Ab studies against a number of 
viral pathogens by ourselves and other investigators, we assume 
that the escape mutants from these nAbs may reflect virus evo-
lution under similar nAb-mediated immune pressure in patients. 
In vitro escape studies showed that a single-amino acid mutation 
at residues Y540 and R542 could confer virus neutralization 
escape from four nAbs (1F8, 3A1, 3C12, and M14D3). For the 
3B11 and 3B12 Abs, which use the germ-line gene of VH1-69*06, 
two escape mutations were observed for each nAb, although 
further investigation indicated that the L506F substitution alone 
could not abrogate 3B11 and 3B12 nAb binding; in contrast, the 
respective Y540C and T512A substitutions resulted in the pro-
found loss of nAb binding activity. Natural virus variation with 
F506 has been reported for England-1 MERS-CoV, which was 
isolated from the second MERS patient from Qatar (51). It is 
possible that 3B11- or 3B12-like nAbs were involved in driving 
the L506F mutation (52). We tested the neutralization of 3B11 
and 3B12 scFvFcs on the England-1 CoV strain, which encodes 
the L506F substitution in the S protein. The respective IC50 
values for 3B11-Fc and 3B12-Fc were 5.48 and 13.8 μg/mL, 
demonstrating that three- or 11-fold higher concentrations were 
required to neutralize the England-1 MERS-CoV strain com-
pared with the EMC/2012 MERS-CoV strain.
The effects of these escape mutations on hDPP4 binding ac-
tivity and viral fitness also are significant. Both BLI and FACS 
assessments of RBD mutants indicated that, except for the 
P547S substitution that was selected by the epitope 1 Ab 1E9, all 
other substitutions exhibited either small (L506F) or significantly 
(T512A, Y540C, R542G) decreases in RBD binding affinity to 
hDPP4 (Table S2). Viral fitness assays demonstrated that the 
P547S substitution slightly enhanced viral fitness, whereas the 
substitutions at positions T512, Y540, and R542 of epitopes 2 
and 3 decreased viral fitness. Although we did not generate 
a viral escape mutant carrying the L506F substitution alone, the 
decrease in binding affinity for hDPP4 caused by the L506F 
substitution may contribute to its decreased viral fitness (25)
(Fig. 5A and Table S2). These results lead us to propose that the 
immunodominance of the human nAb response to the RBD–
hDPP4 interface can restrict MERS-CoV evolution by driving 
virus down an escape pathway that predominantly results in 
a significant cost in viral fitness. In vitro human mAb neutrali-
zation studies on SARS-CoV recapitulated the escape mutations 
that were seen during the SARS outbreak (37). Additionally, 
decreased virulence of the neutralization escape mutants co-
incided with reduced affinity of the mutant SARS-S for its ACE2 
receptor (49). Given the decreased growth kinetics of these es-
caped mutants in vitro, we anticipate that the majority of escape 
mutants selected from similar nAbs in vivo may be attenuated.
In summary, this study identified potent anti–MERS-CoV S 
nAbs that bind to three epitopes at the RBD interface and show 
minimal evidence of cross-epitope resistance. We suggest that 
MERS-CoV vaccines, particularly those that express S in the 
context of virus/VLP membranes, as we describe here, may be an 
effective way to present this vulnerable interface for immune 
recognition (26, 27). In addition, in view of current recom-
mendations by the International Severe Acute Respiratory and 
Emerging Infection Consortium and the increasing recognition 
that human Abs may have a role in the management of infectious 
diseases, the therapeutic potential of these nAbs should be 
considered for the prophylaxis and treatment of MERS (53). 
Although escape from neutralization is a concern with thera-
peutic Abs, our study provides reagents and a strategy to mitigate 
this potential problem. Divergent combination immunotherapy 
uses two different nAbs to non–cross-resistant epitopes to de-
crease the possibility of viral escape while taking advantage of 
synergistic neutralizing effects (37, 49, 54, 55). By virtue of its
Expression and Purification of scFvFcs and Whole Human IgG1. The VH and VL
scFvs of unique positive clones were first cloned into a eukaryotic expression
vector, where the scFv is fused in-frame with the human IgG1 hinge-CH2-CH3
domains. For production of whole human IgG1, the VH and VL gene frag-
ments of scFv were subcloned separately into the human IgG1κ expression
vector TCAE5 or the IgG1λ expression vector TCAE6. These scFvFcs/IgG1s
were transiently transfected into 293F cells, and the cell culture supernatants
were collected twice every 72 h. The expressed scFvFcs and IgG1 were pu-
rified by protein A Sepharose affinity chromatography (GE Healthcare).
S1 Domain Epitope Mapping and Binding Competition. Recombinant soluble
S1(21–358)-hFc, S1(349–751)-hFc, and S1(349–590)-hFc were immobilized to
anti-Flag biosensor at 30 °C for 240 s. The association of 100 nM scFvFcs 1E9,
1F8, 3A1, 3B11, 3B12, 3C12, and M14D3 with each Spike was measured by
using an Octet RED96 (ForteBio, Inc.) for 240 s at 30 °C by exposing the
sensors to 100 nM Ab in 1× kinetic buffer. ScFvFc of F10 was used as a
nonbinding control.
For the binding competition assay, recombinant soluble S1(349–590)-hFc
was bound to an anti-Flag biosensor. The association of each scFvFcs was
measured on the Octet RED96 for 300 s at 30 °C by exposing the sensors to
100 nM scFvFc in 1× kinetic buffer; then the degree of additional binding
was assessed by exposing the sensors to a second scFvFc (100 nM in 1× kinetic
buffer) in the presence of the first scFvFc (100 nM) for 300 s at 30 °C. F10 was
used as a nonbinding control.
Affinity Measurement by Octet. Ab binding affinity was determined using the
same Octet RED96 instrument. Purified S1(349–590)-hFc at 5 μg/mL in 1×
kinetic buffer was immobilized onto anti-Flag biosensors and incubated with
varying concentrations of Abs in solution. All binding data were collected at
30 °C. The experiments included five steps: (i) baseline (60 s); (ii) S1(349–
590)-hFc loading onto sensors (300 s); (iii) second baseline (120 s); (iv) asso-
ciation of Abs for measurement of Kon (300 s); and (v) dissociation of Abs for
the measurement of Koff (600–1,200 s). Baseline and dissociation steps were
conducted in 1× kinetic buffer. Fitting curves were constructed using
ForteBio Data Analysis 7.0 software.
Neutralization Assay with MERS-CoV Spike Pseudotyped Lentivirus. MERS-VLPs
were produced by cotransfecting Lenti-X 293T cells with pcDNA3.1-Sf
(encoding the full-length S of MERS-CoV), pHIV-Luc (encoding the luciferase
reporter gene), and pCMV-ΔR8.2 (encoding HIV gag-pol). Fivefold serially
diluted Abs beginning at 10 μg/mL were incubated in a 96-well plate with an
equal volume of pseudovirus at the final volume of 60 μL at room temper-
ature for 1 h, and the mixture was added to the monolayer of 293T-hDPP4
cells cultured in a luminometer plate (PerkinElmer). Anti-influenza HA F10
Ab (scFvFc and IgG1) was used as the control Ab. VSV-G pseudotyped len-
tivirus was used as the virus control. After overnight incubation, the plate
was replenished with 100 μL fresh medium in each well and cultured for
another 24 h. Luciferase activity was measured by using a luciferase assay kit
(Promega). Briefly, culture medium was removed, cells were lysed by the
addition of 30 μL lysis buffer, and the relative luciferase units in cell lysates
were measured using a POLARstar Omega (BMG Labtech). This assay was
performed in triplicate.
Plaque Reduction Neutralization Test with Live MERS-CoV. MERS-CoV EMC/
2012 was cultured on Vero cells. The neutralization assay was conducted
using a PRNT50 assay as described previously (48, 60). Briefly, serial dilutions
of the Abs in PBS were incubated with 100 pfu of MERS-CoV for 1 h at 37 °C,
and the Ab-virus mix was added to the monolayer of Vero cells, along with
virus without Ab. After 1 h of incubation, overlay-containing medium and
agarose were added, and the plaques formed in each dilution were counted
48–72 h following infection. The percentage of neutralization was calculated
as [(100 − number of plaques with Ab)/number of plaques without Ab)] × 100.
Binding Competition Between scFvFcs and DPP4. Recombinant soluble human
DPP4 was purchased from Abcam. A buffer exchange step to PBS was per-
formed using an Amicon Ultra 0.5-mL centrifugal filter (Millipore). Purified
S1(349–590)-hFc was loaded onto anti-Flag biosensors and incubated first with
100 nM of each scFvFcs. Additional binding of DPP4 was measured by ex-
posing the sensors to 100 nM DPP4 in the presence of the 100 nM scFvFc.
Similarly, anti-Flag biosensors loaded with S1(349–590)-hFc was incubated
with 100 nM of DPP4 followed by monitoring the subsequent binding of
100 nM scFvFc to the sensors in the presence of 100 nM DPP4. All mea-
surements were performed on an Octet RED96.
Ab Inhibition of Spike and MERS-VLP Binding to 293T-hDPP4 Cells. S1(349–590)-
hFc (50 nM) was incubated with scFvFcs (450, 150, 50, or 0 nM) in a 50-μL
volume at 4 °C for 1 h. F10 scFvFc was used as the control. Each mixture was
added to 1 × 105 293T-hDPP4 cells and incubated at 4 °C for 1 h. Cells were
washed three times with PBS containing 0.5% BSA and 0.1% NaN3. For
detection of S1(349–590)-hFc binding to 293T-hDPP4 cells, cells were in-
cubated with mouse anti-Flag Ab at 4 °C for 30 min followed by APC-Cy7–
labeled goat anti-mouse IgG (Pierce). After extensive washing, samples were
analyzed using a BD LSRII.
Similarly, 50 μL MERS-VLP was mixed with scFvFcs (450, 150, 50, or 0 nM)
at 4 °C for 1 h. The mixtures then were added separately to 293T-hDPP4 cells.
After washing, the binding of MERS-VLPs to 293T-hDPP4 cells was monitored
with anti-Flag Ab staining and flow cytometry.
Isolation of the Escape Mutants Under Selective Pressure of nAbs. MERS-CoV
(1 × 106 pfu) was incubated with 30 μg of each Ab in a 200-μL volume of PBS
for 30 min and then was added to a monolayer of Vero cells. The development
of cytopathic effect (CPE) was monitored over 72 h, and progeny viruses
were harvested. Three rounds of selections were performed in the presence
of 30 μg/mL Abs (except for 3B11 scFvFc), and CPE was noted during each
passage. The viruses from final passage were plaque purified in the presence
of Ab, and titers were determined as described (48). The S genes from plaque-
purified viruses were sequenced to identify mutations that conferred escape
from these Abs.
Escape Mutations Affect RBD-Ab Binding and Cross-Neutralization. Seven RBD
mutant derivatives of S1(349–590)-hFc were constructed (Table S2) using
a site-directed mutagenesis kit (Agilent). The mutant RBD proteins were
expressed and purified from transfected 293T cells. The binding affinities of
seven scFvFcs to these RBD mutants were measured on an Octet RED96 as
described above. Furthermore, Ab neutralization against escape mutants
was investigated by PRNT50 assay.
Escape Mutations Affect RBD-hDPP4 Binding and Viral Fitness. The binding
affinity of RBD mutants to hDPP4 was measured first using the Octet RED96.
Because five of seven RBD mutants have undetectable binding to hDPP4, the
RBD-hDPP4 binding was investigated further by FACS. Each RBDmutants was
serially diluted 2× and incubated with 1 × 105 293T-hDPP4 cells in 100 μL of
FACS buffer. After three washings, cells were stained with APC-Cy7–labeled
goat anti-human IgG1. After extensive washing, the samples were analyzed
by using a BD LSRII.
Virus growth kinetics were measured in triplicate by inoculating Vero cells
with different escape mutants at a multiplicity of infection (MOI) of 0.1 for
1 h, after which unbound virus was washed, mediumwas added back, and the
supernatant was sampled at various time points. Virus titers were determined
by plaque assay.
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